



VGX Pharmaceuticals Announces Publication of Preclinical Efficacy Studies for VGX-1027 for Various Inflammatory Diseases

Blue Bell, PA – May 8, 2007 –

VGX Pharmaceuticals announced today the publication of preclinical animal efficacy studies for VGX-1027, the company's lead drug candidate for the treatment of inflammatory diseases such as rheumatoid arthritis (RA) and type 1 diabetes (T1D). As demonstrated in the new paper, VGX-1027 is a novel orally-active, small-molecule compound with broad anti-inflammatory properties.

A research report entitled, "In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: Modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models," was published in the online edition of *Clinical Immunology* (<http://www.sciencedirect.com/science/journal/15216616>) and the print edition should be available in several weeks. *Clinical Immunology* is the official journal of the Clinical Immunology Society. The project was led by Professor Ferdinando Nicoletti of the University of Catania. The co-authors of the paper included VGX Co-founder Dr. J. Joseph Kim.

VGX-1027 is an immune modulator that inhibits production of several pro-inflammatory cytokines that are responsible for the damaging effects of inflammatory diseases. Pre-clinical studies in this paper further show that VGX-1027 is effective in inhibiting these cytokines by blocking NF- κ B and transiently inhibiting the p38 signaling pathway, while JNK and AP-1 pathways are unaffected.

"We are pleased to report on the impressive therapeutic activity of VGX-1027 in several preclinical animal models," said J. Joseph Kim, Ph.D., President and CEO of VGX Pharmaceuticals. "We look forward to moving VGX-1027 into clinical testing as soon as possible."

VGX Pharmaceuticals is developing VGX-1027 as an oral therapeutic for RA. VGX Pharmaceuticals is co-developing VGX-1027 for T1D with its affiliate VGX International. The Investigational New Drug Application (IND)-enabling toxicity studies for VGX-1027 are currently on-going and the IND is planned to be filed in 2H 2007.

Cautionary Factors That May Affect Future Results - Materials in this Press Release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on www.vgxp.com as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About VGX Pharmaceuticals

VGX Pharmaceuticals is a biopharmaceutical company with small molecules and biologics product candidates for the treatment of infectious diseases, cancer and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection and VGX-410C for chronic HCV infection, both of which are currently in Phase II clinical trials. In addition, Phase I clinical trials will be initiated in 2007 for VGX-150 for the treatment of Melanoma and VGX-1027 for inflammatory diseases. VGX's research pipelines include new generation of DNA vaccines and therapeutics as well as CELLECTRA™, a proprietary DNA delivery device. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

Company Contact:

Kevin W. Rassas
Senior Vice President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com